Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Liliemark

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Clinical Pharmacokinetics|February 1, 1997
The clinical pharmacokinetics of cladribineJ Liliemark
Cancer Research|October 15, 1991
On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humansJ Liliemark, G Juliusson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1996
Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemiaG Juliusson, J Liliemark
Blood|February 15, 1992
Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infectionsG Juliusson, J Liliemark
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte countG Juliusson, J Liliemark
Leukemia & Lymphoma|March 1, 1994
Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistanceG Juliusson, J Liliemark
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
Dose escalation of high-dose cyclophosphamide and etoposide with high-dose doxorubicin (CDE) and filgrastim for poor-risk non-Hodgkin's lymphomaG Juliusson, J Liliemark
Archivum Immunologiae Et Therapiae Experimentalis|January 1, 1994
2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerationsJ Liliemark, G Juliusson
Clinical Pharmacokinetics|September 1, 1991
Pharmacokinetic optimisation of anticancer therapyJ Liliemark, C Peterson
Anti-Cancer Drugs|June 1, 1997
Stability and analysis of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine and 2-chloroadenine in human blood plasmaS Lindemalm, F Albertioni, J Liliemark
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Clinical Pharmacokinetics|February 1, 1997
The clinical pharmacokinetics of cladribineJ Liliemark
Cancer Research|October 15, 1991
On the pharmacokinetics of 2-chloro-2'-deoxyadenosine in humansJ Liliemark, G Juliusson
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1996
Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemiaG Juliusson, J Liliemark
Blood|February 15, 1992
Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infectionsG Juliusson, J Liliemark
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1993
High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte countG Juliusson, J Liliemark
Leukemia & Lymphoma|March 1, 1994
Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistanceG Juliusson, J Liliemark
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1996
Dose escalation of high-dose cyclophosphamide and etoposide with high-dose doxorubicin (CDE) and filgrastim for poor-risk non-Hodgkin's lymphomaG Juliusson, J Liliemark
Archivum Immunologiae Et Therapiae Experimentalis|January 1, 1994
2-Chloro-2'-deoxyadenosine--clinical, biochemical and pharmacokinetic considerationsJ Liliemark, G Juliusson
Clinical Pharmacokinetics|September 1, 1991
Pharmacokinetic optimisation of anticancer therapyJ Liliemark, C Peterson
Anti-Cancer Drugs|June 1, 1997
Stability and analysis of 2-chloro-2'-deoxyadenosine, 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine and 2-chloroadenine in human blood plasmaS Lindemalm, F Albertioni, J Liliemark
Pageof 8